Dipharma’s Novel Research on Nitrosamine Detection in APIs
Dipharm a Francis has published an open-access method in Organic Process Research & Development that integrates the nitrosation assay...
eClinical Tech News
Valneva Chikungunya Vaccine Positive in Kids’ Phase 2 Trial
Valneva reported final 12-month antibody persistence and safety results from its Phase 2 pediatric study of IXCHIQ, its single-shot...
Bioversys Launches Promising Phase 3 Trial for BV100 Drug
BioVersys has initiated a global Phase 3 program for BV100 in ventilator- and hospital-acquired bacterial pneumonia caused by drug-resistant...
Amphista Announces New AMX-883 Data, Business Update at ASH
Amphista Therapeutics will present new preclinical data at ASH 2025 for AMX-883, an oral targeted glue degrader of BRD9,...
Onco3r’s SIK3 Inhibitor Completes First Phase 1 Cohort
Onco3R Therapeutics has completed the first multiple-ascending-dose cohort and four single-ascending-dose cohorts in a Phase 1 study of O3R-5671,...
Kala Bio Enters $6M Securities Purchase Agreement with Lazar
Kala Bio has secured a $6 million financing via non-voting convertible preferred stock from private investor David E. Lazar,...
Empaveli Phase 3 VALIANT Results Published for C3G, IC-MPGN
Apellis’ pegcetacoplan has crossed a credibility threshold in rare nephrology: Phase 3 VALIANT results for C3 glomerulopathy and primary...
Lamy Completes Acquisition of Cancer Innovator Exousia AI
LAMY, soon to be rebranded as Exousia Bio (OTCPINK: LMMY), has completed an all‑stock acquisition of Exousia AI, issuing...
Lamy’s Strategic Acquisition of Exousia AI in Cancer Tech
Lamy, set to rebrand as Exousia Bio, has acquired 100% of Exousia AI in an all‑stock deal, issuing 62,223,000...
Iolyx Inks Dry Eye Deal With Théa, Secures Series B Funds
Iolyx Therapeutics has signed a global development and commercialization deal with Laboratoires Théa for ILyx-002 in ocular surface disease,...